Efficacy and tolerability of injectable sodium valproate in patients with mania

doi:10.4103/0019-5545.31603

Indian J Psychiatry. 2006 Apr-Jun; 48(2): 118–120.

doi: 10.4103/0019-5545.31603

PMCID: PMC2913561

Efficacy and tolerability of injectable sodium valproate in patients with mania

R. K. Solanki,^* Paramjeet Singh,^** Renu Khandelwal,^*** and Aarti Midha^****

^*Professor and Unit Head-III Department of Psychiatry, SMS Medical College, Jaipur, Rajasthan

^**Assistant Professor Department of Psychiatry, SMS Medical College, Jaipur, Rajasthan

^***Resident Doctor – Final year Department of Psychiatry, SMS Medical College, Jaipur, Rajasthan

^****Resident Doctor – Final year Department of Psychiatry, SMS Medical College, Jaipur, Rajasthan

Correspondence to:R.K. Solanki, D-840, Malviya Nagar, Jaipur, Rajasthan; e-mail: solanki_ramk/at/yahoo.com

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article has been cited by other articles in PMC.

Abstract

Background:

Sodium valproate is among the newer mood stabilizers and is also an anticonvulsant.

Aim:

To assess the effect of intravenous sodium valproate in patients with acute manic episodes of bipolar disorder.

Methods:

A 1-week open trial was conducted in the year 2004–2005 at the emergency ward of the Psychiatric Centre, SMS Medical College, Jaipur, in which 30 patients participated.

Conclusion:

Substantial improvement was seen. No major side-effects were noted except marginal elevation of the SGOT and SGPT. The findings suggest that injectable sodium valproate is a safe and effective mood stabilizer for patients with mania.

INTRODUCTION

Acute manic excitement is disturbing for patients, their relatives and society. Rapid resolution of acute manic episodes can reduce the substantial personal and economic burden on patients, their relatives and society.

Treatment of bipolar disorder includes anticonvulsants and antipsychotics.¹^–⁵ Conventional neuroleptics such as haloperidol and chlorpromazine and novel antipsychotics such as risperidone, olanzapine and ziprasidon are effective in treating acute mania.¹^,4^,6 The efficacy of neuroleptics in treating manic symptoms is related to their D₂ receptor blockade, while the efficacy of mood stabilizers is related to their own specific mechanism such as blockage of synthesis of IP₃ with lithium, and that of the GABAergic system with sodium valproate.⁴^,5^,7^,8

In the USA, the anticonvulsant divalproex sodium is widely used because of its proven antimanic activity and evidence of long-term protective effect against recurrence of bipolar disorder. Its effects are dependent on the dose and serum concentration.²^,4^,8. To exert an antimanic effect, the plasma therapeutic level should be in the range of 45–150 mg/L.⁹ It has been claimed that rapid resolution of manic symptoms can be achieved with a loading dose of 20 mg/kg/day, which starts after 5 days of therapy.¹⁰ Due to gastrointestinal intolerance and poor compliance in some of the acutely ill patients it was not possible to administer an oral loading dose, hence the injectable route was used.¹⁰^–¹²

This study proposed to test the efficacy of injectable sodium valproate as compared with oral sodium valproate.

METHODS

The current study assessed the efficacy and safety of injectable sodium valproate in an open-label trial, parallel group, randomized comparative prospective study in subjects with acute manic excitement. Thirty patients completed the study. The subjects were recruited from the OPD, Psychiatric Centre, SMS Medical College, Jaipur on the basis of inclusion and exclusion criteria after taking written consent, both from the subjects and their relatives.

Inclusion criteria

Patients between the ages of 18 and 65 years
Patients who fulfilled the ICD-10 criteria for bipolar affective disorder
A score of at least 20 on the 11-item Young Mania Rating Scale (YMRS) at screening¹³
Patients who had not taken any treatment since the past 2 months
Patients who provided written informed consent

Exclusion criteria

Patients with a YMRS score of less than 20
Patients with an organic brain syndrome
Patients with schizophrenia, schizoaffective disorder, epilepsy or any other neurological disorder
Patients with a history of alcohol and drug abuse within 3 months from the start of the study
Patients at imminent risk of causing injury to themselves or others
Patients with serious or unstable medical illnesses
Patients with marked laboratory abnormalities especially liver and renal function tests and haemogram
Patients with a history of severe drug allergy or hyper-sensitivity
Pregnant and nursing women and those with childbearing potential not on adequate contraception
Patients with a significant history of previous liver and renal diseases
Recently relapsed cases were excluded on account of having uniformity of cases in the study group.

Baseline investigations

Complete physical examination
Complete haemogram; pregnancy test
Liver function tests
Renal function tests
ECG

Assessments were done at screening, baseline, day 3 and day 7 by using the YMRS¹³ and clinical global impression scale.¹⁵

Selected patients were admitted in the emergency ward after complete physical examination and baseline investiga-tions. Each case was recorded in detail on a specially designed proforma, which included the consent form, identification data, sociodemographic data and detailed history of bipolar illness and baseline investigations. Patients in the experimental group were given single-blind treatment with either injectable sodium valproate + oral risperidone while those in the control group received oral sodium valproate + oral risperidone.

In the exclusion criteria, a YMRS score less than 20 was an arbitrary dividing line indicating less severe psychopathology, so subjects who scored more than 20 were randomly assigned to two groups.

Injectable sodium valproate was given in dose of 1500–2000 mg/day in divided doses by IV infusion with 500 cc of 5% GDW (maximum 1000 mg at a time).

The dose of oral sodium valproate was also in the range of 1500–2000 mg/day in divided doses. Risperidone can be given in a dose of 4–8 mg/day according to the patient's requirement.

The study medication is available as a parenteral preparation of 5 ml/vial containing 100 mg sodium valproate per ml. The study medication was given in as flexible a schedule as permissible. The investigator had the option to adjust the daily dose depending on individual patient's response or presence of intolerable adverse effects. Pretreatment signs and symptoms, concomitant medications and adverse effects were recorded. Serious adverse events, if any, were recorded separately; vital signs, including the blood pressure, pulse, body weight were recorded daily. Laboratory parameters such as the haemogram, SGOT, SGPT, serum bilirubin, serum urea and serum creatinine were also recorded at baseline, day 3 and day 7.¹¹^,12^,16^,17

The serum sodium valproate levels were measured on day 3 and day 7.

Concomitant medications

No other psychotropic medication was allowed during the trial.
Drug treatment for somatic illnesses was limited as much as possible.
Injectable/oral lorazepam was used as and when required in a dose of up to 2–4 mg/per day.

RESULTS

The results of the paired t test demonstrate a highly significant reduction in the YMRS scores of patients on injectable sodium valproate compared with those on oral sodium valproate as shown in Tables Tables11–3.

Table 1

YMRS score of experimental and control groups

Table 3

Significance of difference on YMRS score on day 7

Table 2

Significance of difference on YMRS score on day 3

In the experimental group, 18 patients showed more than 50% decrease in YMRS scores, 6 patients showed minimal improvement (less than 25%), 4 patients showed no changes and 2 patients become worse at the end of the trial (because of psychotic features).

In the control group, 14 patients showed more than 50% decrease in YMRS scores and 4 patients did not show any changes. In 7 patients the decrease in YMRS score was less than 25%.

Safety

No serious adverse effects were recorded in any patient in the experimental group. In general, adverse effects were mild in intensity and included marginal (benign) elevation of liver enzymes (SGOT and SGPT) to less than 140 IU per ml in 24 patients, flatulence in 1 patient, diarrhoea in 2 patients, vomiting in 3 patients, nausea in 5 patients, thrombophlebitis in 1 patient. Oral loading of sodium valproate resulted in significant elevation of serum SGOT and SGPT (more than 140 IU per ml).

No clinically relevant changes in pulse, blood pressure and heart rate were seen throughout the trial. In addition, there were no clinically relevant abnormalities of the bio-chemical and haematological parameters.

DISCUSSION

Only injectable antipsychotics and benzodiazepines are used to treat acute manic excitement; these have their own limitations. Oral antiepileptics, which are also used, also have their limitations such as poor treatment compliance and GI intolerance. As these patients pose a special problem of compliance in hospital, several studies have recommended an oral loading dose of valproate for such patients, which again has limitations of compliance and GI intolerance.¹⁰^–¹² The authors used injectable valproate to assess its efficacy and limitations in these patients.

The results of this study showed that improvement in the experimental group was statistically significant in comparison with the control group. The results on day 3 and day 7 (Tables (Tables11–3) also show that the improvement was statistically significant. In addition, there were no clinically significant abnormalities in either the biochemical or haematological parameters which would have required discontinuation of the study.¹²^,15 Moreover, the response on CGI-S was also significant in the experimental group compared with the control group (Table 4). Hence, injectable valproate is more efficacious and better tolerated than oral valproate as it reduces manic symptoms more rapidly than oral valproate (Table 3), i.e. on day 3 and day 7. The overall hospital stay was also reduced in the experimental group. The authors recommend that injectable sodium valproate may be used as a first-line drug in the management of acute manic excitement.

Table 4

Improvement of clinical global impression scale

REFERENCES

1. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271:918–24. [PubMed]

2. Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry. 1996;153:765–70. [PubMed]

3. Devane CL, Pharma D. Pharmacokinetis. Drug interaction and tolerability of valproate. Psychopharmacol Bull. 2003;37:25–42. [PubMed]

4. Calabrese JR, Markowitz PJ, Kimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid cycling bipolar patients. J Clin Psychopharmacol. 1992;12:53–6. [PubMed]

5. Chou JC. Recent advances in treatment in acute mania. J Clin Psychopharmacol. 1991;11:3–21. [PubMed]

6. Eadie MJ, Hooper WD, Dicknson RG. Valproate associated hepatotoxicities and its biochemical mechanism. Med Toxicol. 1988;3:85–106. [PubMed]

7. Yathan LN. Safety and efficacy of risperidone as combination therapy for manic phase of bipolar disorder. Int J Neuropsycho-pharmocol. 2000;3:S142. (Suppl 1)

8. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992;149:108–11. [PubMed]

9. Hisrsechfeld RM, Allen MH, McEvoy JP, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry. 1999;60:815–18. [PubMed]

10. Keck PE., Jr A review of randomized controlled clinical trial in acute mania. J Affect Disord. 1983;5:91–6. [PubMed]

11. Pearlson GD, Wong DF, Tune LE, et al. In vivo D2 dopamine receptor density in psychotic and non psychotic patients with bipolar disorder. Arch Gen Psychiatry. 1995;521:471–7. [PubMed]

12. Perucca E, Gatti G, Frigo GM, et al. Pharmacokinetics of valproic acid after oral and intravenous adminstration. Br J Clin Pharmacol. 1978;5:313–18.

13. Young RC, Bigs JT, Ziegler VE, et al. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35. [PubMed]

14. Pope HG, Jr, McEtroy SL, Keck PE., Jr Valproate in the treatment of acute mania: Placebo-controlled study. Arch Gen Psychiatry. 1991;48:62–8. [PubMed]

15. Spearing M, Post R, Leuerich G, et al. Modification of the clinical Global Impression (CGI) scale for use in bipolar illness (BP): The CGI for bipolar disorder—the CGI-BP. Psychiatry Res. 1997;73:159–71. [PubMed]

16. Waldmeier PC. Is there is a common denominator for the antimanic effect of lithium and anticonvulsants? Pharmaco-phsychiatry. 1987;20:37–47. [PubMed]

17. Wilder BJ, Kras BJ, Penry KK, et al. Gastrointestinal tolerance of divalproex sodium. Neurology. 1983;33:808–11. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of
Medknow Publications